2025
Changes in Cardiovascular Risk Factors and Health Care Expenditures Among Patients Prescribed Semaglutide
Lu Y, Liu Y, Totojani T, Kim C, Khera R, Xu H, Brush J, Krumholz H, Abaluck J. Changes in Cardiovascular Risk Factors and Health Care Expenditures Among Patients Prescribed Semaglutide. JAMA Network Open 2025, 8: e2526013. PMID: 40779264, PMCID: PMC12334959, DOI: 10.1001/jamanetworkopen.2025.26013.Peer-Reviewed Original ResearchConceptsHealth care expendituresCardiovascular risk factorsCare expendituresCohort studyRisk factorsYale New Haven Health SystemCohort study of adultsType 2 diabetes statusLong-term impactStudy of adultsHealth systemRetrospective cohort studyBlood pressureHemoglobin A1c reductionMain OutcomesTotal cholesterolSentara HealthcareInpatient staySecondary outcomesGlucagon-like peptide-1 receptor agonistsPrimary outcomeHealthPeptide-1 receptor agonistsAssociated with clinical outcomesAssociated with reductions
2024
Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer
Michikawa C, Gleber-Netto F, Pickering C, Rao X, Wang J, Sikora A, Myers J, Frederick M. Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer. Oral Oncology 2024, 153: 106729. PMID: 38663156, DOI: 10.1016/j.oraloncology.2024.106729.Peer-Reviewed Original ResearchConceptsOral cavity squamous cell carcinomaAssociated with clinical outcomesExtranodal extensionLymph node metastasisImmune infiltrationImmune infiltration statusOverall survivalPrimary tumorNode metastasisOral cancerInfiltration statusClinical outcomes of OSCC patientsExtension of lymph node metastasesAssociated with clinical outcomes of patientsAssociated with OS rateLocally advanced oral cancerClinical outcomes of patientsOutcome of OSCC patientsAssociated with poor overall survivalImmune infiltration of tumorsLow immune infiltrationNode negative tumorsAdvanced oral cancerHuman papillomavirus-negativeInfiltration of tumorsEvolution of the functionality of microbial communities in patients with metastatic renal cell carcinoma (mRCC) receiving cabozantinib (cabo)/nivolumab (nivo) with or without CBM588: A randomized clinical trial.
Ebrahimi H, Meza L, Lee K, Malhotra J, Alcantara M, Zengin Z, Dizman N, Hsu J, Llamas-Quitiquit M, Castro D, Mercier B, Barragan-Carrillo R, Chawla N, Li X, Liu S, Chehrazi-Raffle A, Dorff T, Frankel P, Tripathi A, Pal S. Evolution of the functionality of microbial communities in patients with metastatic renal cell carcinoma (mRCC) receiving cabozantinib (cabo)/nivolumab (nivo) with or without CBM588: A randomized clinical trial. Journal Of Clinical Oncology 2024, 42: 460-460. DOI: 10.1200/jco.2024.42.4_suppl.460.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaMetabolic pathwaysClinical outcomesAnnotated open reading framesFunction of microbial communitiesMetatranscriptomic sequencing dataWhole metagenome sequencingOpen reading frameGut microbial functionsGut microbiome functionsResponse rate to sorafenibExperimental armElectron transfer chainCancer cell typesAssociated with clinical outcomesRenal cell carcinomaReading frameSequence dataTaxonomic profilesBiosynthesis pathwayMetagenomic sequencingMicrobiome functionMicrobial functionsMolecular functionsRandomized clinical trials
2021
Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology
Reardon B, Moore N, Moore N, Kofman E, AlDubayan S, Cheung A, Conway J, Elmarakeby H, Imamovic A, Kamran S, Keenan T, Keliher D, Konieczkowski D, Liu D, Mouw K, Park J, Vokes N, Dietlein F, Van Allen E. Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology. Nature Cancer 2021, 2: 1102-1112. PMID: 35121878, PMCID: PMC9082009, DOI: 10.1038/s43018-021-00243-3.Peer-Reviewed Original ResearchConceptsMolecular profilingAssociated with clinical outcomesIdentified therapeutic strategiesTumor molecular profilingIndividual's molecular profileMolecular featuresGenomic dataOpen-source computational methodClinical outcomesRetrospective cohortTrial cohortGenomic alterationsTherapeutic strategiesTherapeutic approachesPoint-of-care decision makingPrecision oncologyGlobal molecular featuresPatientsClinical hypothesisCohortClinical frameworkKnowledge basesAlterations
2020
Neoantigens in Patients with De Novo Follicular Lymphoma: Results from the PRIMA Study
Henneges C, Jin D, Venstrom J, Trabucco S, Nielsen T, Penuel E, Huet S, Salles G, Paulson J. Neoantigens in Patients with De Novo Follicular Lymphoma: Results from the PRIMA Study. Blood 2020, 136: 25-26. DOI: 10.1182/blood-2020-134795.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaDe novo diffuse large B-cell lymphomaProgression-free survivalTumor mutational burdenComprehensive genomic profilingCurrent equity holderAssociated with progression-free survivalFollicular lymphomaF. Hoffmann-La RocheFoundation MedicinePrognostic valueClinical outcomesMedian tumor mutation burdenProgression-free survival eventsPooled analysis of patientsLarge B-cell lymphomaResponse to induction treatmentCalculate tumor mutational burdenAssociated with clinical outcomesEZH2 mutation statusComprehensive genomic profiling dataB-cell lymphomaGenetic mutational landscapeAnalysis of patientsProportion of patientsPrimary membranous nephropathy in children and adolescents: a single-centre report from South Asia
Ramachandran R, Nayak S, Kumar V, Kumar A, Agrawal N, Bansal R, Tiewsoh K, Nada R, Rathi M, Kohli H. Primary membranous nephropathy in children and adolescents: a single-centre report from South Asia. Pediatric Nephrology 2020, 36: 1217-1226. PMID: 33108509, DOI: 10.1007/s00467-020-04798-8.Peer-Reviewed Original ResearchConceptsAssociated with clinical outcomesPartial remissionFollow-upImmunosuppressive therapyClinical outcomesMembranous nephropathyPatients treated with rituximabSymptom onset to presentationBiopsy-proven pMNSingle-centre reportsMedian Follow-UpFirst-line therapyPrimary membranous nephropathyMethodsThis prospective studyPercentage of patientsChildhood nephrotic syndromeMedian proteinuriaAnti-PLA2RMycophenolate mofetilMedian intervalMedian ageResistant diseaseClinical presentationNo significant differenceClinical behaviorAbstract A65: Longitudinal detection of TERT-mutant plasma cell-free circulating tumor DNA in newly diagnosed glioblastoma patients
Cordova C, Syeda M, Corless B, Wiggins J, Patel A, Kurz S, Delara M, Sawaged Z, Utate M, Placantonakis D, Golfinos J, Schafrick J, Silverman J, Jain R, Snuderl M, Zagzag D, Karlin-Neumann G, Polsky D, Chi A. Abstract A65: Longitudinal detection of TERT-mutant plasma cell-free circulating tumor DNA in newly diagnosed glioblastoma patients. Clinical Cancer Research 2020, 26: a65-a65. DOI: 10.1158/1557-3265.liqbiop20-a65.Peer-Reviewed Original ResearchCell-free circulating tumor DNAPlasma cell-free circulating tumor DNADroplet digital PCRTumor DNAClinical outcomesDroplet digital PCR assayGBM patientsC228TC250TTERT mutationsIDHwt glioblastomasPlasma samplesLiquid biopsyPost-RT follow-upPromoter mutations C228TTERT promoter hotspot mutationsNewly diagnosed GBM patientsAssociated with clinical outcomesMonitoring of glioblastomaMonths post radiationDiagnosed glioblastoma patientsGross total resectionPromoter hotspot mutationsIDH wild-typeFFPE tumor samples
2019
Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel.
Thomas M, James S, Becker R, Himmelmann A, Katus H, Cannon C, Steg P, Siegbahn A, Lakic T, Storey R, Wallentin L. Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. European Heart Journal Acute Cardiovascular Care 2019 PMID: 33609104, DOI: 10.1177/2048872619878075.Peer-Reviewed Original ResearchWhite blood cell countBaseline inflammatory markersTicagrelor compared to clopidogrelBlood cell countInflammatory markersC-reactive proteinAcute coronary syndromePrimary endpointCardiovascular deathCell countNeutrophil countClinical outcomesAcute coronary syndrome treated with ticagrelorCoronary syndromeCardiovascular benefitsN-terminal pro-brain-type natriuretic peptideInterleukin-6Increased risk of adverse cardiovascular eventsQuartile of white blood cell countComposite of cardiovascular deathAssociated with clinical outcomesRisk of adverse cardiovascular eventsLevels of inflammatory markersAcute coronary syndrome patientsPLATO study
2015
Interobserver and Intraobserver Reliability of the Modified Waldenström Classification System for Staging of Legg-Calvé-Perthes Disease
Hyman J, Trupia E, Wright M, Matsumoto H, Jo C, Mulpuri K, Joseph B, Kim H, Casey V, Castañeda P, Choi P, de Barros F, Gilbert S, Gourineni P, Hennessey T, Herring J, Janicki J, Kelly D, Kessler J, Larson A, Laine J, Logan K, Mack P, Martin B, Mehlman C, Otsuka N, Rosenfeld S, Sankar W, Schrader T, Shore B, Stuecker R, Sundberg S, Tamai J, Tis J, White K. Interobserver and Intraobserver Reliability of the Modified Waldenström Classification System for Staging of Legg-Calvé-Perthes Disease. Journal Of Bone And Joint Surgery 2015, 97: 643-650. PMID: 25878308, DOI: 10.2106/jbjs.n.00887.Peer-Reviewed Original ResearchConceptsLegg-Calve-Perthes diseaseIntraobserver reliabilityAssociated with clinical outcomesLegg-Calve-PerthesKappa valuesRadiographs of patientsSurvey 1Interobserver kappa valuesPediatric orthopaedic surgeonsClinical outcomesIntraobserver agreementClassification systemSurvey 3Orthopaedic surgeonsSurgeonsDiseaseOutcome studies
1997
High Telomerase Activity in Primary Lung Cancers: Association With Increased Cell Proliferation Rates and Advanced Pathologic Stage
Albanell J, Engelhardt M, Han W, Moore M, Lonardo F, Rusch V, Langenfeld J, Klimstra D, Venkatraman E, Dmitrovsky E. High Telomerase Activity in Primary Lung Cancers: Association With Increased Cell Proliferation Rates and Advanced Pathologic Stage. Journal Of The National Cancer Institute 1997, 89: 1609-1615. PMID: 9362159, DOI: 10.1093/jnci/89.21.1609.Peer-Reviewed Original ResearchConceptsNon-small-cell lung cancerTumor cell proliferation ratePatients treated with surgeryAdvanced pathological stageTelomeric repeat amplification protocolPathological stageLung cancerCell proliferation rateHigh telomerase activityTelomerase activityTumor stageKi-67Clinical outcomesResected non-small-cell lung cancerAssociated with tumor pathologic stagePrimary non-small-cell lung cancerImmunohistochemical analysis of Ki-67Proliferation rateMultivariate Cox proportional hazards analysisTNM (tumor-node-metastasis) stageTumors treated with surgeryAnalysis of Ki-67Associated with clinical outcomesLong-term follow-upAssess tumor cell proliferation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply